IntelGenx Grants Stock Options

(firmenpresse) - SAINT-LAURENT, CANADA -- (Marketwired) -- 01/19/17 -- IntelGenx Technologies Corp. ("IntelGenx", or the "Company") (TSX VENTURE: IGX)(OTCQX: IGXT) announced today that the Company's board of directors granted options to acquire a total of 300,000 common shares under the 2016 Stock Option Plan.

Of the total stock options granted, 50,000 were granted to each of the following non-employee directors Bernard Boudreau, John Marinucci, Ian Troup, Bernd Melchers, Clemens Mayr and Mark Nawacki. The options were granted as part of the annual compensation for non-employee directors. The options have an exercise price of US$0.89 (CAD$1.16), vest immediately, and expire on January 17, 2027.

About IntelGenx:

IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. Established in 2003, the Montreal-based company is listed on the TSX-V and OTC-QX.

IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: .

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.

Source: IntelGenx Technologies Corp.



Contacts:
IntelGenx Technologies Corp.
Ingrid Zerbe
Corporate Secretary
514-331-7440

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: Marketwired
Datum: 19.01.2017 - 21:15 Uhr
Sprache: Deutsch
News-ID 518811
Anzahl Zeichen: 0

contact information:
Town:

SAINT-LAURENT, CANADA

Kategorie:

Health & Nutrition

Diese Pressemitteilung wurde bisher 390 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"IntelGenx Grants Stock Options"
steht unter der journalistisch-redaktionellen Verantwortung von

IntelGenx Technologies Corp. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

IntelGenx Submits Montelukast VersaFilm(TM) Clinical Trial Application With Heal ...

SAINT-LAURENT, QUEBEC -- (Marketwired) -- 11/09/17 -- IntelGenx Corp. (TSX VENTURE: IGX)(OTCQX: IGXT) (the "Company" or "IntelGenx"), today announced that it has submitted a clinical trial application ("CTA") to Health ...

IntelGenx Reports Third Quarter 2017 Financial Results ...

SAINT-LAURENT, QUEBEC -- (Marketwired) -- 11/09/17 -- IntelGenx Technologies Corp. (TSX VENTURE: IGX)(OTCQX: IGXT) (the "Company" or "IntelGenx") today reported financial results for the third quarter ended September 30, 2017. A ...

IntelGenx to Report Third Quarter 2017 Financial Results on November 9, 2017 - C ...

SAINT-LAURENT, QUEBEC -- (Marketwired) -- 11/02/17 -- IntelGenx Technologies Corp., (TSX VENTURE: IGX)(OTCQX: IGXT), today announced that it will release its third quarter 2017 financial results after market close on November 9, 2017.An accompanying ...

Alle Meldungen von IntelGenx Technologies Corp.